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Senescence, from the shortening of telomeres, accumulation of mutations, epigenetic hypomethylation, and
other causes, begins an eventual cycle of decline in every patient. Stem cells disappear as a function of age,
which in turn impairs cellular replication. Moreover, when fully differentiated cells are induced back into
induced pluripotent stem cells (iPSCs), they not only revert to a state of pre-differentiation, but also to a
younger cellular age. Their aging clocks turn back: their telomeres become longer and DNA methylation
reverts back to an earlier age. It should therefore be possible to use iPSCs to replace the missing stem cells
from aged organs and tissues and to replace existing, older tissue with younger cells. In order to accomplish
this, this paper will also explore new nanotechnological mechanisms in generating patient-specific scaffolds,
including two-photon polymerization, a fabrication process that uses a specifically focused, near-infrared
laser to build three-dimensional scaffolds. This paper finally proposes a mechanism to apply iPSCs as pre-
ventative medicine, to replace aging organs before they fail and unwind the aging clock to lengthen healthspan.
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I. Introduction
While tremendous progress has been made in length-
ening human lifespans by combating disease, senescence
and aging in general have been intractable. However,
aging affects everyone and reducing the effects of aging
would alleviate many other diseases as well. As such, ag-
ing and senescence research is incredibly important and
relevant in the field of preventative medicine.
Rather than suggesting technologies to help improve
one’s lifespan, this review will identify a potential solu-
tion to extending one’s healthspan—that is, the portion
of their life that they spend healthy. As one ages, they
are more prone to two different types of diseases. Ap-
proaching middle age, high-risk individuals aged 30-54
years tend to experience premature chronic diseases. On
the other hand, older adults aged 65-89 years, with gener-
ally weakened immune systems, have an increased likeli-
hood for fatal diseases including respiratory illness, heart
problems, and mental illnesses including Parkinson’s and
Alzheimer’s diseases1.
Thus, age impacts every organ of the body and can
cause many of them to fail. Currently organ failure
can be treated by transplanting a healthy organ from
a (sometimes deceased) donor, replacing the failed or-
gan in the patient. However, there are numerous prob-
a)Electronic mail: ctech22@ohs.stanford.edu
lems with this system. First, the transplants themselves
are typically complex surgical procedures. Transplants,
particularly those involving live donors, often also carry
immense ethical considerations to minimize harm to the
donor2. Furthermore, large shortages cripple many pa-
tients’ ability to receive an organ, particularly within a
crucial window for an aged body. The waiting list for a
kidney transplant in the United States has grown to over
83,000 people by the end of 2009, yet only 16,500 people
received an organ transplant throughout 20092. There-
fore, it is quite possible for someone to die while on the
waiting list for a transplant to replace their aging organ.
Further issues plague existing transplants with organ
transplant rejection. Rejection of the organ transplant
may occur as the immune system’s B and T lymphocytes
attack the foreign organ or through non-immunological
reasons such as ischemia/reperfusion injury3. With these
detriments, current transplants typically only have a half-
life of 15 years for kidneys, and in other cases, a single
lung transplant has one of just 6 years3. This limited
lifespan coupled with the shortage further diminishes a
transplant’s ability to resolve aging permanently, making
a standard transplant more of a temporary bandage to a
much deeper problem.
This review will explore a different solution to current
methods of organ transplants to alleviate the effects of
aging, outlined in Figure 1. Induced pluripotent stem
cells are undifferentiated from skin cells to be differenti-
ated again into any possible cell type. In undifferentiat-
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FIG. 1. A graphical abstract for the proposal presented
throughout the paper. Somatic cells are taken from a pa-
tient and undifferentiated into induced pluripotent stem cells.
These iPSCs are then redifferentiated into other somatic cells
through transcription factors. These somatic cells are placed
upon extracellular scaffolds constructed from ultrafine two-
photon polymerization specific to a patient’s needs. In this
process, the new artifical organs are constructed from a pa-
tient’s own genome while featuring extended telomeres, more
active mitochondria, and a younger epigenome.
ing somatic human cells, the cells’ internal aging clocks
rewind, retroactively decreasing of the effects of aging.
These differentiated cells have the patient’s own genome
and surface proteins, so they are not marked as foreign
substances by the body’s immune system. Additionally,
as these can be generated from excess skin cells, they
do not rely on a fixed supply from other members of a
population.
These differentiated stem cells can then be placed upon
an artificially synthesized scaffold to build an artificial or-
gan. The two-photon polymerization mechanism allows
for high resolution, biocompatible scaffold designs for the
most complex organs. This novel combination of tech-
niques could provide a new approach to organ transplants
that are made from the patient’s own cells specific to a
patient’s complex needs. Organ transplants becoming a
more accessible and personalized opportunity could also
lead to voluntary transplants that would prevent the ef-
fects of aging ahead of organ failure. After binding these
induced pluripotent stem cells to a customizable scaffold
unique to each patient, researchers can replace old tis-
sues and organs with new tissues from a patient’s own
cells to help increase their healthspan and help them live
a healthier life for a longer time.
II. Senescence: Aging as a Disease
Senescence, known more colloquially as aging, is the
process of slow decay and destruction that affects every
human throughout their adult life. Therefore, aging can
be classified as the disease with 100% prevalence and,
ceteris paribus, 100% fatality. As a result, aging and its
effects are incredibly significant to each and every indi-
vidual. In addition to crippling the body’s tissue, aging
also increases one’s susceptibility to disease4.
There are many compounding causes of aging, all of
which impact different organs at different times. Several
different causes include telomeres, genetic mutations, or-
ganelle deterioration, and epigenetic impacts.
A. Telomeres
Telomeres are repeating, non-coding sequences of DNA
that cap each chromosome, to prevent DNA damage to
the expressive genes, genetic degradation, and end-to-
end fusions between chromosomes5. With each mitotic
replication, their length decreases. As a person ages,
their telomeres continuously shorten, reducing the pro-
tection of their chromosomes. Telomeres additionally
have a multiprotein structure known as shelterin that
prevents chromosomes fusing together as a repair tech-
nique if telomeres become damaged. Without this struc-
ture, cells show increased senescence4.
Telomeres shorten per replication cycle due to the
telomeres’ lack of a template for DNA polymerase to
replicate. In embryonic stem cells, the telomerase en-
zyme replenishes the telomeres by providing a template4.
This enzyme is not expressed in adult somatic cells, but
is present in induced pluripotent stem cells (explored fur-
ther in Section III E). However, Jaskelioff et al found that
reintroducing telomerase via a knock-in mechanism into
somatic cells in mice not only increased telomere length,
but also reduced DNA damage signaling, removed an un-
desirable aging phenotype in organs, and even reverted
neurodegeneration6. Thus reduced levels of telomerase
have some effect on aging. Clearly, telomeres are not only
useful toward preventing mutations, but also in providing
the key to understanding and even reversing senescence
itself.
B. Aging and the Genome
Senescence also greatly damages the genome in all
cells, both from accumulated mutations and decreased
efficacy of DNA repair mechanisms. A summary of the
genetic effects of senescence can be found in Figure 2.
Genetic mutations that impair tissue function are
quite common with senescence. As one ages, DNA be-
comes more damaged, as body heat breaks down the
sugar-phosphate backbone and increased DNA hydrol-
ysis causes more apruinic and apyrimidinic sites—DNA
locations with only one unpaired nitrogenous base8. This
damaged DNA is then even more prone to genetic mu-
tations, worsening aging further over time. In mice,
point mutations and genetic rearrangements increase
with age, reflecting affected transcriptional activity and
metabolism7. The mutation rate for a generation is
around 2.5× 10−8 per nucleotide site, so the more repli-
cations that are made, the more DNA replication will
mutate the genome each cycle9. Ramsey et al found that
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FIG. 2. A framework for many of the causes of aging. Senes-
cence itself hurts stem cells, driving the importance for new
iPSCs to be added to the body. Eventually, unrepaired DNA
damage leads to p53 activation (a pathway for cancer) and
senescence/apoptosis, as well as direct impairment of cellular
function7.
human chromosomes also experience translocations and
insertions at a steeper cubic rate with respect to one’s
age10. Therefore, in addition to the accumulation of
mutations throughout life, senescence makes these mu-
tations more common. Similar effects are seen in other
genetic material. Martin et al found that the mutation
rate for a particular genetic region in epithelial cells in
kidneys from 72 donors rose from a frequency of approx-
imately 5 × 10−5 in the first 10 years of life to approx-
imately 2.5 × 10−4 past 80 years, an five-fold increase.
They found that like chromosomal aberrations, these mu-
tations increase at an exponential rate11.
In essence, senescence leads to greater deterioration
of genes. However, this deterioration can lead to more
senescence as well. Apoptosis protects against ge-
netic mutations, with damaged and senescent cells self-
terminating. However, if mutations decrease apoptosis,
this can eventually lead to cancer, which will exhaust the
body’s immune system and, especially with chemother-
apy, age the body further. On the other hand, cell death
itself is a signature of many other age-related diseases
such as Alzheimer’s and Parkinson’s8. Therefore, the
impact of senescence upon mutations creates a deadly
positive feedback loop: senescence causes less apoptosis,
which can cause cancer, which, alongside chemotherapy,
drives increased senescence.
C. Epigenetic Aging
Senescence additionally impacts the epigenome. The
epigenome controls the expression of genes through en-
vironmental factors and can involve promotion or deac-
tivation of particular genes.
DNA methylation involves the attachment of a non-
polar methyl group (CH3) to a gene to deactivate its tran-
scription. As a person ages, hypomethylation (a decrease
of methyl tags in the epigenome, promoting expression of
previously blocked genes) and hypermethylation (an in-
crease of methyl tags in the epigenome, blocking tran-
scription of previously expressed genes) become more
prevalent, depending on the gene12. In one instance,
as senescence progresses, DNMT1, a DNA methyltrans-
ferase responsible for copying epigenetic methyl tags to
newly copied DNA, has decreased activity and expres-
sion, leading to loss of genomic imprinting (hereditary
epigenetic expression information passed down from pro-
genitors) and early death in mice13. Decreased expres-
sion of DNMT1 leads to hypomethylation with a loss of
methyl tags between cell generations, as well as cell cycle
arrest12. The effects of DNMT1 are further explored in
section III E on Stem Cells and Cancer.
In addition to methylation changes, there are sev-
eral other epigenetic factors that are impacted by ag-
ing. Shortened telomeres lead to fewer binding sites for
a repressor activation protein Rap1, a protein that aids
telomere length regulation and telomere silencing12,14.
As a result, Platt et al (in a yeast based study using
Saccharomyces cerevisiae mutants without telomerase to
model senescence) found that Rap1 relocated to 491 new
genes after senescence. The second most significant new
category of gene targets included the nuclear nucleosome,
particularly the genes for core histone proteins H2A,
H2B, H3, and H414. Histones wind and condense a DNA
sequence into chromatin. The unorganized DNA—that
is, DNA wound more loosely around fewer histones—is
more susceptible to errors including pre-mRNA splicing
during transcription12. Therefore, telomere shortening
causes a repressor protein Rap1 to bind to new sources,
causing a decrease in epigenetic protection of the genome,
which all contribute further to senescence.
One other age-related epigenetic change pertains to
ncRNAs, or non-protein-coding RNA, that is transcribed
by expressed exons of DNA but does not build a protein
during translation. During aging, the expression of vari-
ous ncRNAs changes dramatically, and while these ncR-
NAs do not code for proteins, they do perform other tasks
such as regulating gene expression12. There are many
other senescence-dependent epigenetic factors, as well as
proposed mechanisms for addressing them in humans,
that are beyond the scope of this paper, but clearly,
the environment and expression of particular genes both
changes with respect to and affects senescence.
III. Stem Cells and Aging
Stem cells offer a potential solution to these detrimen-
tal effects of aging in their ability to differentiate into
new tissue. Due to this pluripotency, stem cells are a
candidate for generating artificial organs to replace fail-
ing ones. While many different types of stem cells occur
naturally, induced pluripotent stem cells can be formed
from somatic skin cells, differentiate into nearly any kind
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of cell, and even unwind the aging process.
A. Adult Embryonic Stem Cells
Stem cells are the basis for all cells in the human
body. Pluripotent stem cells in the blastocyst—also re-
ferred to as embryonic stem cells (ESCs)—differentiate
into all types of human tissue starting four days after
fertilization15. As such, research into harvesting stem
cells is important, as these cells could differentiate into
any tissue needed for organ transplants, artificial organs,
and repair of trauma damage.
Since these cells only exist in the blastocyst, it is un-
fortunately usually necessary to destroy the blastocyst in
the process of harvesting the ESCs. This has raised large
ethical concerns regarding whether or not the benefits
of scientific research outweigh destruction of the blasto-
cysts. More recently, however, there are studies explor-
ing the possibility of harvesting individual blastomeres
(ESCs) from human embryos without their destruction
through a biopsy method16.
Regardless of the ethical concerns, one of the benefits
of stem cells is that they possess the genetic informa-
tion of the host, which means organs made from these
cells would not appear as foreign substances, reducing
the chance of an undesirable immune response. Assum-
ing the new technique mentioned was not used when a pa-
tient was an embryo, embryonic stem cells cannot create
younger tissues for a current adult patient, since ESCs
no longer exist within an adult.
Another type of stem cell is the adult stem cell (ASC).
Most cells in adults undergo a process of mitosis, where
aging cells divide into two new daughter cells. However,
some cells, such as neurons and bone marrow, do not go
through mitosis at their death. They are instead replaced
by the differentiation of adult stem cells.
ASCs are more stable, but are not as pluripotent as
embryonic stem cells. They reside in specific tissues, pri-
marily to repair damage or replenish other organs. For
instance, ASCs include hematopoietic stem cells (HSCs),
which reside in bone marrow and differentiate exclusively
into a variety of new blood cells, as shown in Figure 3.
As a result, ASCs cannot differentiate into any type of
cell, but only into certain types17.
Adult stem cells possess some key advantages over
ESCs. Because of ESCs’ pluripotency, they are quick
to proliferate and grow, which also happens to define
the problems of cancer. Therefore, ESCs are more likely
to grow into tumors than ASCs. In addition, ASCs do
not trigger the dangerous immune response seen in how
the immune system attacks some ESCs with mismatched
mitochondria18. Thus, while ASCs have limited differen-
tiation potency (for example, HSCs would have to be har-
vested from bone marrow and could only become blood
cells), they are more stable and less likely to become can-
cerous.
B. Induced Pluripotent Stem Cells
Induced pluripotent stem cells, on the other hand, fo-
cus on in vitro creation of stem cells that mimic the
FIG. 3. The differentiation of hematopoietic stem cells, or
HSCs, an adult stem cell in bone marrow that replenishes
blood cells. Other differentiation paths not depicted in-
clude the common myeloid progenitor becoming a neutrophil,
eosinophil, or basophil17.
pluripotency of ESCs beyond the embryonic state. Start-
ing from somatic cells (typically skin cells), researchers
use Yamanaka (or Thomson) factors to reprogram the so-
matic cell into the induced pluripotent stem cell (iPSC),
which is then differentiated into virtually any somatic
cell. Essentially, iPSCs share the same functionality as
ESCs, but they are easier to obtain and circumvent the
moral concerns of destroying a blastocyst19.
iPSCs were first developed in studies by Yamanaka and
Thomson. In a 2007 paper titled “Induced Pluripotent
Stem Cell Lines Derived from Human Somatic Cells,” Yu
et al showed how four genes—OCT4, SOX2, NANOG,
LIN28–(henceforth referred to as “transacting factors”)
along with a lentiviral vector to knock in one gene, could
undifferentiate a human somatic IMR90 (lung) cell into
an iPSC. They then showed how these iPSCs demon-
strated high telomerase activity and ESC cell surface
antigens absent in the IMR90 control cell but present in
the H1 ESC. Further, Yu et al used teratoma formation
to show how these iPSCs could differentiate into ecto-
dermal, mesodermal, and endodermal tissue. The results
collectively confirm that these are indeed stem cells20.
After undifferentiating the somatic cell into an iPSC,
the iPSC must be differentiated into the intended final
cell. Most approaches include mimicking the normal dif-
ferentiation process of ESCs that occurs during develop-
ment. One approach is to enable certain transcription
factors that guide a iPSC into a particular class of cell.
However, a more biocompatible and successful approach
pertains to adding external growth factors and inhibitors
to even more closely mimic natural development21. In
this way, the iPSC receives extracellular signals to differ-
entiate into a specific class of cell.
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Between their creation and differentiation, iPSCs pro-
vide an ethical and efficient way of taking disposable hu-
man cells and crafting entirely new tissue. They do not
have the limit of versatility as adult stem cells, nor the
ethical and logistical challenges of harvesting embryonic
stem cells from a blastocyst only 3-5 days after fertil-
ization. As a result, iPSCs could be used to build an
organ from a patient’s own cells, bypassing any immune
response or genetic incompatibilities.
C. Stem Cells and Senescence
As stem cells age, they deteriorate and change func-
tion. As mentioned above, ASCs lack the same pluripo-
tency of ESCs as stem cells begin to settle into cer-
tain limited tracks of differentiation. For instance,
hematopoietic stem cells (HSCs) from the embryo and
HSCs from an adult have different alleles and pheno-
types. For example, in 1995 Morrison et al studied the
differences between HSCs in fetal liver and HSCs in bone
marrow and found that the fetal cells expressed the anti-
gen Mac1+, whereas the cells in the bone marrow were
Mac1−. Comparing these with previous research, Mor-
rison et al hypothesized that Mac1+ could be a factor
for more proliferating cells22. Indeed, Rydstrom and
Larsson supported these findings, suggesting that Mac1+
cells have much greater regenerative activity during early
stages compared to Mac1− cells, but this disparity de-
creases as the cells age in later stages of regeneration23.
Both of these show not just the impact of Mac1 on HSCs,
but that older HSCs phenotypically differ from younger
ones as they age, causing a decrease in proliferation. This
suggests that the stem cells themselves change to prolif-
erate less as they age.
There are also other effects as stem cells age. They
experience changes in cell cycles, with Bowie et al noting
stem cells display much more frequent and more active
S/G2/M phases until 2-4 years after birth, followed by a
sudden decline to adult-like HSC cycling frequency24,25.
This decline leads to less stem cell proliferation from less
replication. This abrupt change, Bowie et al suggest, is
caused by the shortening of telomeres at even the infant
level, let alone the adult level later on in life25. These,
taken along with the effects of senescence on all cells cov-
ered above, show how stem cells become much more lim-
ited as a function of age, and how embryonic stem cells
remain the natural favorite for pluripotent abilities.
D. Undifferentiation Reverses Aging
These problems impact natural stem cells, yet for iP-
SCs, the undifferentiation process contains anti-aging
abilities before differentiating into a new somatic cell
again. In essence, transforming somatic cells into iP-
SCs makes the cells more youthful and therefore fixes
numerous problems present in both aging somatic cells
and aging stem cells.
Sarkar et al carried out a range of experiments on
how nuclear reprogramming factors alleviate aging ef-
fects. They analyzed fibroblasts and endothelial human
cells from young and older donors, alongside a number of
nuclear reprogramming factors including OCT4, SOX2,
and NANOG, among others. After injecting mRNA for
these factors, Sarkar et al found that the DNA methyla-
tion age as measured by an epigenetic clock decreased by
up to 4.94 years in endothelial cells26. This epigenetic ag-
ing process occurs as more genes are unused, more receive
methyl (CH3) attachments to disable that gene’s expres-
sion. As such, Sarkar et al’s study found that the nuclear
reprogramming factors undo this methylation process to
the level of 4.94 years younger in endothelial cells (and
1.84 years younger in fibroblasts).
Sarkar et al’s experiments discovered other aging phe-
nomena that diminished under nuclear reprogramming
factors. In both fibroblasts and endothelial cells, mito-
chondrial membrane potential—an indication of cellular
respiration and metabolic rates—increased from the older
cells’ rate, with the mean potential of the fibroblasts
exceeding even the younger cells. The iPSCs also dis-
played a lower accumulation of reactive oxygen species.
These findings, along with other findings of reversing ef-
fects from age-related diseases such as osteoarthritis, are
promising in showcasing the importance of involving nu-
clear reprogramming factors and stem cells to reverse the
aging process26. Notably, however, all of these findings
come from the nuclear reprogramming factors before the
somatic cells pass a “point of no return” into a stem cell,
meaning that some impacts of the reversal of aging do
not even require the entire concentration of nuclear re-
programming factors to fully undifferentiate the cells.
Cells that continue to undifferentiate past that point
of no return to become iPSCs offer some even greater ad-
vantages. Many studies have explored the link between
telomere length and stem cells, and how induced pluripo-
tent stem cells compare to embryonic stem cells. Marion
et al differentiated mouse embryonic fibroblasts (MEFs)
with four of the nuclear reprogramming factors (Oct3/4,
Sox2, Klf4, cMyc) to generate four factor iPSCs. While
embryonic stem cells had an average telomere length of
121.0 kilobases (Kb) and the somatic MEF’s mean length
was 30.7 Kb, the iPSCs possessed a mean telomere length
of 78.4 Kb27. This represents a nearly 255% increase
in telomeres from somatic cells, bringing the telomere
length compared to the ESC from 25.4% in the MEF to
around 64.8% in the iPSC.
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FIG. 4. An overview of the aging benefits beyond telomeres
achieved through undifferentiating an old cell into an iPSC.
From an old cell to a re-differentiated somatic cell, telom-
eres are extended, mitochondria are rejuvenated, and methy-
lations in the epigenome are removed making the cell have a
younger function, while the DNA mutations from senescence
remain28.
While iPSCs can regrow telomeres, the extent of this
regrowth and the stability of the telomeres is currently
under more research. Studies such as Vaziri et al suggest
that while most iPSC lines do have reduced telomerase
activity after a certain point that prevent iPSC telomeres
from regrowing to the length of those found in ESCs, one
cell line out of six with relatively high telomerase ac-
tivity did regrow the full ESC telomere over 60 days29.
After differentiation, studies diverge even further, with
some suggesting that differentiated iPSC telomeres de-
grade quickly. Others suggest that telomeres can last in
certain subpopulations, with telomeres in iPSCs derived
from centenarians lasting over 110 mitosis cycles, twice
that of normal aged individuals28. There are many other
age-related benefits to iPSCs and the undifferentiation
process, as highlighted in Figure 4. Clearly, the nuclear
reprogramming factors allow older cells newer promise in
induced pluripotent stem cells that have a younger epige-
netic clock, higher metabolic rates, and longer telomeres.
These features of induced pluripotent stem cells imply
that organs created from them would be younger cells
that should last longer and have less illness, increasing
their lifespan even further beyond traditional transplants.
This revelation would also make voluntary organ trans-
plants, where a patient chooses to replace an aging organ
with their own stem cells, possible to prevent the effects
of aging in advance.
E. Stem Cells and Cancer
Stem cells are not without their negative impact, how-
ever. Cancer stem cells, or CSCs, share an ability for
pluripotency along with a quick replication process, not
unlike the freqeunt S/G2/M cycles shown in Bowie et
al24,30. Adult stem cells, on the other hand, do have lim-
its on their cycles and potency to mitigate the chance of
tumor growth. However, unlike even ESCs, CSCs have
high levels of ABC/MDR transporter proteins—proteins
that push foreign substances out of the cell—that may
help them avoid destruction by removing chemother-
apy drugs. To an even larger extent than ESCs, CSCs
demonstrate extraordinarily deregulated self-renewal and
survival techniques allowing the cell to bypass pro-
grammed cell death—apoptosis—or checkpoints in the
mitosis process30. CSCs begin to act with the unregu-
lated properties of ESCs in a structured adult.
Indeed, CSCs—while normally the minority in number
for any given tumor—are responsible for much of the tu-
mor’s growth31. While there are many cells in a tumor,
CSCs contain the ability to self-renew and grow expo-
nentially, not only growing the tumor but allowing it to
metastasize as well.
CSCs usually descend from other stem cells (mainly
ASCs). Stem cells typically wait until a stimulant from
their environment to differentiate and renew; however,
a genetic mutation can cause the cell to become au-
tonomous and morph into a CSC32. Therefore, CSCs
develop in regions with higher concentrations of stem
cells, such as leukemia from HSCs and brain tumors
from neural stem cells30. One particular example per-
tains to chronic granulocytic leukemia (CGL). In 1974,
Nowell found that a ‘Philadelphia’ (Ph) gene was present
in 85-90 percent of “neoplastic”—tumorous—cells, going
so far as to suggest that a prognosis for CGL should only
be made with the presence of the Ph gene33. It is the
presence of this gene on chromosome 22 that increases
the ‘stemness’ of the tumor—increasing cell proliferation,
blocking apoptosis, and causing the stem cells to escape
from their niche34.
There are many other mechanisms for the develop-
ment of CSCs, as well, beyond a genetic mutation as
presented above. CSCs are thought to develop in in-
numerable ways, ranging from field theory—that some
niches (areas of stem cells) do not regulate differentiation
as tightly—to epigenetic environmental changes—such as
sun exposure driving melanoma34. This risk of cancer is
crucial to acknowledge when designing stem cell-based
organs, as the risk of cancer is very real even with adult
stem cells. With more potent iPSCs, the risk of develop-
ing CSCs only increases further. However, differentiating
the cells to form an organ in vitro reduces the concern
for cancer instead of inserting the iPSCs directly into a
niche.
The DNA methyltransferase DNMT1 (from Section
II C) has an effect on stem cells and cancer as well.
DNMT1 promotes stemness properties of embryonic
stem cells by methylating certain genes that promote
senescence and limit differentiation. In this way, Tsai
et al demonstrate how DNMT1 is necessary in ESCs for
differentiation and proliferation, as when they created
a cell line transfected with shRNA (short hairpin RNA
for RNA interference), these stem cells experienced a de-
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crease in proliferation and differentiation and an increase
in expression of genes pertaining to aging13. Therefore,
it may seem that research should simply look into keep-
ing the activity and expression of DNMT1 constant, as
this would improve stem cell performance and limit aging
effects.
However, stem cells and cancer have many of the same
origins. Al-Kharashi et al found that not only is DNMT1
upregulated in fibroblasts with breast cancer and that ec-
topic expression of the gene increases carcinogenic effects,
but that a knockout of DNMT1 through siRNA (small
interfering RNA; another RNA interference technique in
addition to shRNA) decreases the production of cancer-
causing proteins including SDF-1 and TGF-β1. Further,
Al-Kharashi et al identify a positive feedback loop be-
tween DNMT1, the IL-6 protein, and STAT3, allowing
a tumor to grow and proliferate. Thus, Al-Kharashi et
al conclude that DNMT1 actively causes a breast can-
cer tumor form and grow, while also promoting stem cell
proliferation35.
Clearly, the distinction between stem cell and cancer is
a fine line, as a gene designed to promote stem cell pro-
liferation and growth that is impacted by and affects ag-
ing may also cause tumorigenesis. For general stem cell
research, then, researchers must be cautious that their
methods promoting stem cell pluripotency and prolifera-
tion do not cause cancer in their patients.
IV. Scaffolds in Tissue Engineering
The induced pluripotent stem cells are only half of the
story. In intact tissues, cells are attached to a larger
superstructure, such as an extracellular matrix. When
researchers create the iPSCs to build an artificial tissue
or organ, they must also find a structure upon which to
attach these cells. These structures are known as scaf-
folds.
A scaffold must fulfill a number of functions to anchor
iPSCs within a larger system. First, cells must be able to
bind to and grow upon such a scaffold. A scaffold must
also provide structural soundness and reliability, as well
as featuring a connection to the rest of the body for ex-
tracellular communication. Scaffolds must also provide a
space for remodeling as cells divide and wounds repair36.
This section will review existing methods to create scaf-
folds for iPSCs as well as outline a new method that uti-
lizes nanolithography and two photon-polymerization.
A. Porous Scaffold Design
Porous scaffold designs (PSDs) use natural bioma-
terials such as bioadhesive peptides and olgiosaccha-
rides or synthetic biomaterials such as polycaprolactone
(PCL) that create a rigid structure to maintain a certain
volume37,38. The porous nature of the structure allows
important receptors and materials from the body to enter
through the organ into its cells38.
Although these materials are similar to the kind used
in animal bodies, there are still concerns over biocom-
patibility. Some researchers have identified possible solu-
tions to antigenic reactions including removing telopep-
tides (proteins that cause immune system reactions) in
procollagen, a strong carrier molecule for the release of
proteins36,39. Further concerns surround the structural
integrity of PSDs without synthetic material.
FIG. 5. Two of many SFF fabrication processes for porous
scaffold designs. (A) Stereolithography uses masked laser
light and a photopolymer to fabricate a scaffold. (B) 3D
printing combines a liquid adhesive inkjet head with pow-
der to build a structure layer-by-layer. There are also other
methods for greater flexibility in different workflows38.
Despite these challenges, porous scaffold designs have
remained popular amongst researchers, particularly for
their ease of fabrication. One framework is to insert
porogens—that is, compounds (such as CO2) that even-
tually dissolve into pores—into a biomaterial to create
the porous nature of the PSD36. Solid freeform fabrica-
tion (SFF) involves a layering mechanism where a 3D bio-
material is developed one layer at a time. Two methods
illustrated in Figure 5 include stereolithography, where
a laser projects onto a substrate to polymerize a liquid
biomaterial into a specific solid, and 3D printing, where
an inkjet head of liquid material moves across a low-
ering piston to print new layers of a scaffold38. There
are many other fabrication processes for PSDs, allow-
ing for a tremendous assortment of possible structures
to be crafted and materials to be used. As such, the
nature of the porous scaffold design fabrication process
allows for new structures to be created using computer-
aided-design, rather than being limited to a fixed group
of existing structures.
B. Decellularizing an Extracellular Matrix
Another method for designing a scaffold relies on us-
ing an existing extracellular matrix, removing its cells
through a decellularization process, and adding the new
iPSCs in their place to create a functioning organ or tis-
sue. These applications include heart valves, muscle ele-
ments, and nerves36.
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One of the appeals of this method is for more complex
structures: it may be difficult to design a section of a
kidney, but by using a scaffold from a different animal,
one does not need to design a CAD model for the intricate
nuances behind the structure of the kidney.
To decellularize tissue, rapid temperature oscillations
or ionic solutions dissolve the cell membrane before
trypsin and detergent separate and remove the compo-
nents within each cell36. This process then leaves the ex-
tracellular matrix behind and also removes many of the
antigens that would cause incompatibility in the porous
design approach. Additionally, the extracellular matrix
maintains some features from its previous life. A decellu-
larized extracellular matrix still contains growth factors,
which promote certain cellular behaviors, such as pro-
moting or blocking the formation of blood vessels or bone
tissue40. These factors will ultimately help to connect
the cells to the superstructure and outside environment,
and the decellularization process does not remove these
extracellular connections.
However, unlike the porous scaffold design approach,
this method does involve harvesting an extracellular ma-
trix in the first place. Similar to the ethical concerns
behind harvesting ESCs from blastocysts, one must har-
vest and destroy an existing organ before use. Further,
these organs usually come from other animals. As such
they do not directly resemble human organs and must
be adapted for human transplants. Decellularized extra-
cellular matrices therefore provide an intricate scaffold
for stem cells with support for epigenetic growth factors,
with ethical and practical caveats in requiring the use of
a deceased animal’s organ.
C. Two Photon Polymerization
Traditional scaffolds as detailed above do offer many
necessary characteristics of an artificial extracellular ma-
trix in biocompatibility, biofactor support, and fabrica-
tion processes. However, many lack in vivo studies and
have limited specificity. While the decellularized extra-
cellular matrix scaffold may solve the problem of meticu-
lously fabricating small blood vessels and other complex
intricacies of certain organs, it also requires obtaining
an extracellular matrix from another animal and adapt-
ing that to humans, whereas other traditional fabrica-
tion processes such as PSDs have difficulty creating sub-
stances with the incredibly high degree of precision nec-
essary to replicate some structures.
Nanofabrication processes, on the other hand, are
built to solve these challenges. Used widely in
the semiconductor industry, nanolithography’s most
common form—photolithography—unsurprisingly mir-
rors the stereolithography process used for PSDs with
a much closer resolution, where ultraviolet light passed
through a pre-designed mask either removes or firms pho-
toresist atop a substrate to create a nanostructure. How-
ever, this process requires designing a mask, which is
particularly useful for mass-market products such as con-
sumer electronics processors, yet poses difficulties for the
unique patient-specific design of stem cell scaffolds. An-
alyzing another emerging field of nanolithography, two-
photon polymerization enables highly customizable and
precise scaffolds to be fabricated.
FIG. 6. (A) The single-photon polymerization (1PP) pro-
cess creates planar products on the plane of a photoresis-
tive resin through free radical reactions and UV light. (B)
The two-photon polymerization (2PP) process creates three-
dimensional products through the surface of the resin through
free radical reactions and a near infrared laser, with a vari-
able, highly specific focus41.
As Wu and Gu explain, two-photon polymerization
(2PP) involves two photons exciting a few molecules from
a normal state |1〉 to a higher quantum state |2〉. One
reactant in this reaction is the initiator, which is the sub-
strate coated with photoresist. Photoresist is a substance
that changes its molecular composition through photonic
reactions. 2PP’s chemical reaction uses two near infrared
(NIR) photons alongside such an initiator to create free
radicals, which polymerize with monomers also created
by this process, layer by layer, as shown in Figure 6B41.
Summarized, Wu and Gu state the 2PP reaction is,
2~νNIR + initiator substrate→ R+ + monomers
→ polymerization
The laser uses femtosecond (10−15 seconds) pulses with
very narrow focal lengths to create precise resolutions
below 100nm42. For scale, some of the smallest capillaries
approach 5µm, or around 5000nm. A red blood cell is
around 7 µm. Clearly, this process allows researchers
the ability to build structures on a scale appropriate for
building tissues.
While single-photon polymerization (1PP) does exist,
where ultraviolet light would create a free radical poly-
merization reaction within the photoresistive resin as
seen in Figure 6A, 1PP is restricted to creating planar
substances. In contrast, the combination of two photons
in 2PP, as seen in Figure 6B, along with the specific fo-
cus of the NIR light compared to ultraviolet light, enable
researchers to adjust the focus of the laser to be at any
depth within the photoresistive resin, allowing for three-
dimensional materials to be fabricated within the resin41.
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As 2PP technology has matured, more biocompatible
materials have been found. Negative photoresists are
substances that polymerize when exposed to light, leav-
ing the unexposed areas to be washed away when the sub-
stance is rinsed with a developer. Liao et al suggest that
some negative photoresists that are compatible with the
human body include polylactic acid (PLA), trimethylene
carbonate (TMC), and hydrogels42. While the former
two are standard synthetic polymers, hydrogels are cre-
ated through cross-linking multiple hydrophilic polymers,
making them flexible through fabrication shapes and able
to absorb 1000 times as much water as their own mass43.
While the response to external stimuli must be further re-
searched, their exceptional strength and biocompatibility
make them exceptional candidates for materials of scaf-
folds built through two-photon polymerization. These
scaffolds, combined with induced pluripotent stem cells,
together form a comprehensive potential artificial organ
that reduces the effects of aging.
V. Senescence, Stem Cells, and Scaffolds
The concepts of senescence, stem cells, and scaffolds
are clearly interrelated. Stem cells require a scaffold in
order to integrate into the body. Aging can be partially
solved through a combination of new organs replacing
failing organs as well as induced pluripotent stem cells
rewinding their internal aging clocks. Therefore, future
studies and development in artificial tissues and organs
must involve the connection between undifferentiating
human somatic cells into induced pluripotent stem cells
and designing a customizable scaffold specific to each pa-
tient’s needs. Two-photon polymerization offers a unique
advantage over both porous scaffold design and decel-
lularizing an existing extracellular matrix, as its sub-
100 nanometer resolution allows for more specific tissues,
while its synthetic nature does not require conforming a
different animal’s extracellular matrix to the needs of a
patient. Innovation in these methods can hopefully pro-
vide more organs to alleviate the waiting period required
for many transplants. The ability to grow new tissues
from a patient’s own cells, in addition to removing the
need for an external donor, should improve biocompati-
bility and reduce immune responses for replacing organs
at risk of failure.
Further, new stem cell and scaffolding methods can im-
pact senescence in preventative medicine. Since stem cell
undifferentiation reverses the aging process by length-
ening telomeres and returning methylation stages to an
earlier age, preventative medicine can also use stem
cells and scaffolds for inessential yet preventative or-
gan transplants26,27. In this way, organs can be re-
placed before they fail, which should lengthen healthspan
as younger organs should perform more efficiently than
older organs, as well as providing a less painful life with
less senescence.
Before fully endorsing this path, researchers must be
cautious to avoid cancerous results from promoting stem
cells, as seen with DNMT1 35. Additionally, more bio-
comaptible materials should be found and writing speed
for two-photon polymerization should be increased. Nev-
ertheless, a cure to senescence and a longer healthspan
could involve artificial organs with newly differentiated
somatic cells from induced pluripotent stem cells on cus-
tomized scaffolds fabricated using two-photon polymer-
ization.
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